Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.
[BACKGROUND] This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).
APA
Chen G, Bao Y, et al. (2026). Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.. Future oncology (London, England), 22(4), 467-477. https://doi.org/10.1080/14796694.2025.2565827
MLA
Chen G, et al.. "Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.." Future oncology (London, England), vol. 22, no. 4, 2026, pp. 467-477.
PMID
41020525
Abstract
[BACKGROUND] This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).
[RESEARCH DESIGN AND METHODS] 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.
[RESULTS] Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.
[CONCLUSIONS] The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.
[RESEARCH DESIGN AND METHODS] 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.
[RESULTS] Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.
[CONCLUSIONS] The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.
MeSH Terms
Humans; Female; Breast Neoplasms; Middle Aged; Sentinel Lymph Node; Lymphatic Metastasis; Sentinel Lymph Node Biopsy; Adult; Aged; Biomarkers, Tumor; Thrombin Time; ROC Curve; Fibrinogen; Prognosis
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
- Text-Guided Multi-stage Cross-perception Network for Medical Image Segmentation.
- ALDH1L1 reverses CD8 T cell exhaustion in the oral squamous cell carcinoma microenvironment by reprogramming L-glutamate metabolism.
- Efficacy and safety of tislelizumab as neoadjuvant treatment in patients with stage II-III microsatellite instability-high/mismatch repair-deficient colorectal cancer: a single-arm, multicenter, open-label, prospective, phase II study.
- Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma treated with TACE combined with systemic therapy.